Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease

NCT03252535 is registered in ClinicalTrials.gov with Azidus Brasil as lead sponsor.

NCT NCT03252535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03252535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease
Lead sponsor
Azidus Brasil
Phase
Phase 2
Overall status
Completed
Start date
January 15, 2018
Completion date
April 30, 2021
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease